Personalized cell therapy shows promise for tough cervical cancers
NCT ID NCT03108495
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 study tested a personalized treatment called LN-145 for women with recurrent or advanced cervical cancer. The therapy uses a patient's own tumor-fighting immune cells, grown in a lab and infused back. The trial aimed to see if it could shrink tumors, but it was terminated early, limiting the data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LN-145 (tumor infiltrating lymphocytes, a personalized cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could point toward a new treatment option for women with advanced cervical cancer that has not responded to standard therapies.
What could go wrong
The trial was terminated early, so results are limited. Cell therapies are complex, expensive, and may cause serious side effects like severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Medisch Centrum
Amsterdam, AZ, 1105, Netherlands
-
Allegheny Health
Pittsburgh, Pennsylvania, 15224, United States
-
Augusta University
Augusta, Georgia, 30912-0003, United States
-
Avera Medical Group Oncology
Sioux Falls, South Dakota, 57105, United States
-
Bristol Haematology and Oncology Centre
Bristol, England, BS2 8ED, United Kingdom
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France
-
Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie
Lausanne, Switzerland
-
Centre Léon Bérard
Lyon, 69008, France
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Clínica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Gustave Roussy Cancer Campus
Villejuif, 94805, France
-
Guy's & St.Thomas NHS Foundation Trust
London, SE1 9RT, United Kingdom
-
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital Universitari Vall d'Hebrón
Barcelona, 08035, Spain
-
Hospital Universitario Madrid Sanchinarro
Madrid, 28050, Spain
-
Inselspital
Bern, CH-3010, Switzerland
-
Institut Català d'Oncologia
Barcelona, 08908, Spain
-
Istituto Europeo di Oncologia
Miano, Milano, 20141, Italy
-
James Graham Brown Cancer Center
Louisville, Kentucky, 40202, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
LSU Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53225, United States
-
NHS Greater Glasgow and Clyde
Glasgow, Scotland, G12 0YN, United Kingdom
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Rutgers University
Newark, New Jersey, 07103, United States
-
Sarah Cannon Research Institute London
London, England, W1G 6AD, United Kingdom
-
St. Joseph's Hospital and Medical Center Center For Women's Health
Phoenix, Arizona, 85013, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287-0013, United States
-
UPMC Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University College London Hospitals NHS Foundation Trust
London, England, W1G 6BW, United Kingdom
-
University of California San Diego
San Diego, California, 92093, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Florida Health Cancer Center
Orlando, Florida, 32806, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of South Florida H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Southern California
Los Angeles, California, 90033, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, 01307, Germany
-
Universitätsklinikum Erlangen
Erlangen, Bavaria, 91054, Germany